Alexander Swan
Public Communications Contact at AUTOLUS THERAPEUTICS PLC
Net worth: - $ as of 29/04/2024
Network origin in Alexander Swan first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 27 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Alexander Swan via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| IMMUNOMEDICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | President Corporate Officer/Principal | |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Investment Managers | Director/Board Member Corporate Officer/Principal | |
| University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree | |
Les Laboratoires Servier SAS
 Les Laboratoires Servier SAS Pharmaceuticals: MajorHealth Technology Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France. | Pharmaceuticals: Major | Director/Board Member | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Director/Board Member Private Equity Investor | |
| EPIGENOMICS AG | Medical Specialties | Director/Board Member Director/Board Member | |
| BLUEBIRD BIO, INC. | Biotechnology | Director of Finance/CFO Director/Board Member | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| The University of Texas at Austin | College/University | Corporate Officer/Principal | |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Hospital/Nursing Management | Corporate Officer/Principal | |
| MEDIAN TECHNOLOGIES | Medical/Nursing Services | Director/Board Member | |
| SUCAMPO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member General Counsel | |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Other Consumer Services | Corporate Officer/Principal | |
| London Business School | College/University | Masters Business Admin Masters Business Admin | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member General Counsel | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Avon Foundation For Women
 Avon Foundation For Women Investment Trusts/Mutual FundsMiscellaneous Avon Foundation For Women provides granting services. The non-profit company is based in New York, NY. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Chairman | |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Medical Specialties | Director/Board Member | |
| European Organisation for Research & Treatment of Cancer | Corporate Officer/Principal | ||
The Cancer Prevention & Research Institute of Texas
 The Cancer Prevention & Research Institute of Texas BiotechnologyHealth Technology Cancer Prevention & Research Institute of Texas provides cancer research and prevention programs and services. It is the state agency mandated to create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer. The company was founded in 2007 and is headquartered in Austin, TX. | Biotechnology | Corporate Officer/Principal | |
Institut Gustave Roussy EURL
 Institut Gustave Roussy EURL Miscellaneous Commercial ServicesCommercial Services Institut Gustave Roussy EURL is a cancer research and treatment center that places innovation at the heart of its services. The private company is based in Chevilly-Larue, France, and has subsidiaries in France. The center has strong partnerships at national and international levels to provide high-value care to all its patients. Patients' rights are protected and guaranteed to ensure their autonomy, respect for their individual liberties, and dignity within the hospital. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Pharmaceuticals: Major | Director/Board Member | |
| Sarcoma Alliance for Research through Collaboration | Director/Board Member | ||
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| JUNO THERAPEUTICS INC | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| The Indiana University School of Medicine | College/University | Corporate Officer/Principal | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Founder | |
| BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Median Technologies, Inc.
 Median Technologies, Inc. Medical/Nursing ServicesHealth Services Part of MEDIAN Technologies SA, Median Technologies, Inc. provides medical imaging services. The company is based in Burlington, MA. The CEO of the company is Fredrik Bjjorn Brag. | Medical/Nursing Services | Director/Board Member | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member Chairman | |
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Miscellaneous Commercial Services | Director/Board Member | |
Mariana Oncology, Inc.
 Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Biotechnology | Director/Board Member Director of Finance/CFO | |
Kirilys Therapeutics, Inc.
 Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Medical/Nursing Services | Founder | |
| NCI Experimental Therapeutics Program | Corporate Officer/Principal |
Statistics
International
| United States | 31 |
| United Kingdom | 10 |
| France | 5 |
| Germany | 3 |
| Switzerland | 2 |
Sectoral
| Health Technology | 29 |
| Consumer Services | 8 |
| Health Services | 7 |
| Commercial Services | 4 |
| Finance | 3 |
Operational
| Director/Board Member | 162 |
| Corporate Officer/Principal | 59 |
| Independent Dir/Board Member | 53 |
| Chairman | 40 |
| Director of Finance/CFO | 24 |
Most connected contacts
| Insiders | |
|---|---|
| John Johnson | 40 |
| Kapil Dhingra | 39 |
| Martin Murphy | 33 |
| William Young | 32 |
| John Berriman | 24 |
| Joseph Anderson | 19 |
| Cynthia Butitta | 16 |
| Jay Backstrom | 15 |
| Robert Azelby | 15 |
| Linda Bain | 15 |
| Andrew Oakley | 14 |
| Christian Itin | 12 |
| Robert Iannone | 11 |
| Elisabeth Leiderman | 10 |
| Robert Dolski | 8 |
- Stock Market
- Insiders
- Alexander Swan
- Company connections
